Stress Studies of Tenofovir Disoproxil Fumarate by HPTLC in Bulk Drug and Pharmaceutical Formulation

<table>Densitogram of standard tenofovir disoproxil fumarate 100 ng/spot; Peak 1 (<svg height="16.2875" id="M3" style="vertical-align:-4.77652pt" version="1.1" viewbox="0 0 19.700001 16.2875" width="19.700001" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,16.2875)">
<g transform="translate(72,-58.97)">
<text transform="matrix(1,0,0,-1,-71.95,63.79)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑅</tspan>
</text>
<text transform="matrix(1,0,0,-1,-62.7,60.66)">
<tspan style="font-size: 8.75px; " x="0" y="0">𝑓</tspan>
</text>
</g>
</g>
</svg>: 0.49 ± 0.03), mobile phase-chloroform : methanol (9.0 : 1.0 v/v).</table>

The Scientific World Journal

fig2

Figure 2

Figure 2: Stress Studies of Tenofovir Disoproxil Fumarate by HPTLC in Bulk Drug and Pharmaceutical Formulation 